At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Primary Vaccination Course in Children Receiving the Pneumococcal Vaccine GSK 1024850A or Prevenar™ Co-administered With Hiberix™
In Brief
A Phase 3 clinical trial evaluating Pneumococcal vaccine GSK1024850A (Synflorix), Prevenar, and 1 other intervention for Infections, Streptococcal. Completed, enrolled 503 participants across 14 sites.
Detailed Summary
The purposes of this study are: To demonstrate the immunogenicity in terms of antibody response following primary vaccination of Korean infants with the pneumococcal conjugate vaccine GSK 1024850A compared to Prevenar™ when co-administered with a Haemophilus influenzae type b (Hib) vaccine in children during the first 6 months of life. To evaluate the safety/reactogenicity in terms of solicited and unsolicited symptoms and serious adverse events following primary vaccination of Korean infants with the pneumococcal conjugate vaccine GSK 1024850A.
Study Details
Timeline
Interventions
3 doses administered intramuscularly.
3 doses administered intramuscularly.
3 doses administered intramuscularly.